Brief: Personalis Announces New Data From A Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
16/10/2025 14:04
Oct 16 (Reuters) - Personalis Inc PSNL.O: PERSONALIS ANNOUNCES NEW DATA FROM A LANDMARK LUNG CANCER TRIAL UTILIZING ULTRASENSITIVE MRD TESTING PERSONALIS INC - ANNOUNCES NEW DATA FROM ASTRAZENECA LUNG CANCER TRIAL PERSONALIS INC - NEXT PERSONAL TEST USEFUL IN ASSESSING TREATMENT RESPONSE POST-CRT Source text: ID:nBw8GRc1Ma Further company coverage: PSNL.O
Recent news on Personalis
See all newsBrief: Personalis - Announces Commercial Launch Of Real-Time Variant Tracker In Next Personal Mrd Test
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
Personalis slips as BTIG downgrades, sees no rival bid for Tempus deal
Brief: Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP
Personalis, Inc. reports results for the quarter ended June 30 - Earnings Summary